相关实验视频

Updated: Jan 7, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

在PNH患者中产生血栓,这些患者被连续治疗Eculizumab和Ravulizumab:对对分析

Mario Biglietto¹, Rosaria Mormile¹, Martina Gherardini¹

¹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Journal of thrombosis and thrombolysis

|December 9, 2025

概括

拉夫利祖马布和eculizumab是C5抑制剂,用于阳性夜间血红蛋白尿 (PNH),对血栓生成具有相似的影响. 拉武利祖马布在较少的剂量下提供持续的补充抑制,在PNH患者中保持血静平衡.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

阴性夜间血红蛋白尿 (PNH) 是一种罕见的疾病,由于补充介导的血液溶解,具有高血栓风险.
补充抑制剂如eculizumab和ravulizumab在PNH中减少了血栓栓塞事件.
与eculizumab相比,ravulizumab提供了延长的剂量间隔.

研究的目的:

为了比较ravulizumab和eculizumab对PNH患者凝血动态的影响.
评估长效C5抑制是否保持血静平衡与短效C5抑制相比.

主要方法:

来自9名PNH患者的配对血样本的回顾性分析.
连续使用eculizumab和ravulizumab进行治疗.
血栓生成试验 (TGA) 用于评估凝血动态.

主要成果:

热血素生成试验 (TGA) 参数在拉夫利祖马布和埃库利祖马布治疗之间在很大程度上是可比的.
在ravulizumab治疗期间观察到显着较短的开始尾部时间 (p=0.04),表明较短的血栓生成持续时间.
在血液溶解标记,PNH克隆大小或血液计数方面没有发现显著差异.

结论:

拉武利祖马布和eculizumab在PNH患者的血栓生成上表现出类似的作用.
拉夫利祖马布较短的启动尾时间与其持续的补体抑制相一致.
拉夫利祖马布的长期作用C5抑制似乎相当于eculizumab在PNH中保持静血平衡.

关键词:

凝血是凝固的过程.补充抑制剂的补充抑制剂帕洛克斯夜性血红素尿.血生成试验测定

更多相关视频

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...